And I am not defending Joe at all. Everyone I hope knows exactly what he did and did not do. Actually, what everyone at the companies did and did not do.

My actual point is, there is an actual fact that a cancer drug was tested successfully, a 10 year study and paper was written. That in itself was successful and was outside anything concerning Joe. The value was based on the cancer drug and it actually is what made Joe a bit unhappy because from my understanding, he was expecting more due to Covid research, etc...

So, all in all, NGIO should be valued at least based on the cancer research for breast cancer which was a success in a 10 year study and not on anything Joe accomplished or completely messed up in.